Pfizer Corporation

Bristol-myers Squibb Compnay

Rinat Neuroscience Corporation

Five Prime Therapeutics, Inc.

Amgen Fremont Inc.

Cellectis

Allogene Therapeutics, Inc.

Arvind Rajpal

Pavel Strop

Haichun Huang

Javier Fernando Chaparro Riggers

David L Shelton

Brigitte Devaux

Peter Brams

Thomas John Van Blarcom

Tracy Chia-Chien Kuo

Kristopher Toy

Alan J Korman

Jaume Pons

Wei-Hsien Ho

Paul O Sheppard

Barbra Johnson Sasu

Heidi N Leblanc

Philippe Duchateau

Ginger Chao Rakestraw

Alexandre Juillerat

Mohan Srinivasan

Guodong Chen

Russell Dushin

David B Passmore

Julien Valton

Mark J Selby

Larry L Green

Nils Lonberg

Maria N Jure-Kunkel

Richard Y Huang

Yasmina Noubia Abdiche

Roman Galetto

Aaron Paul Yamniuk

Meina Liang

Karin Ute Jooss

Karla Ann Henning

Michelle Minhua Han

Laurent Poirot

Roberto Crea

Stanley Richard Krystek, Jr

Gregory D Vite

Yong Zhang

Kent B Thudium

Changyu Wang

Han Chang

Mark F Maurer

Paul E Morin

Julianne Smith

Toshihiko Takeuchi

Xi-Tao Wang

Indrani Chakraborty

Brenda L Stevens

Weihsien Ho

Ronald P Gladue

Magdalena Grazyna Dorywalska

Shu-Hui Liu

Wei Chen

Jochem Gokemeijer

Wei Liao

Yik Andy Yeung

Leila Marie Boustany

Andrew Rankin

Yanli Wu

Rory Francis Finn

Keith Sadoon Bahjat

Thomas Charles Pertel

Bryan C Barnhart

Huiming Li

Alexander T Kozhich

Barrett Richard Thiele

Robert J Johnston

Edward Derrick Pascua

Yi Wu

Luis Borges

Lin Hui Su

Lan Yang

Sawsan Youssef

Cesar Adolfo Sommer

Jun Zhang

Ekaterina G Deyanova

Bradley T Keller

Ming Lei

Helen Kim Cho

Andy X Deng

Sandra V Hatcher

Liang Schweizer

Akbar Nayeem

Chetana Rao-Naik

Donna Marie Stone

Randy Shen

Jeffrey Raymond Chabot

Thomas D Kempe

Hong Liang

Sirid-Aimee Kellermann

Michael Quigley

Gerald Fries Casperson

Guido Cappuccilli

Susan Chien-Szu Wong

Mark A Moffat

Bruce Charles Gomes

Xiang Shao

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Antibodies binding to VISTA at acidic pH

Antibodies binding to vista at acidic pH

The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).

Chimeric antigen receptors targeting B-cell maturation antigen

The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.

Therapeutic antibodies and their uses

Universal antibody libraries are described which are synthetic and derived from expressed human antibody sequences selected accordingly to certain criteria, for example, that the sequences are derived from naturally-occurring antibodies expressed in response to a certain antigen class (e.g., small molecule, polysaccharide, peptide, or protein) and having CDR regions engineered for optimal diversity. Methods for making and screening such libraries for isolating therapeutics suitable for treating disease are also disclosed.

Universal antibody libraries

A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.

Prodruggable antibodies, prodrugs thereof, and methods of use and making

The present invention provides transglutaminase-mediated antibody-drug conjugates with high anti-body-drug ratio (DAR) comprising 1) glutamine-containing tags, endogenous glutamines, and/or endogenous glutamines made reactive by antibody engineering or an engineered transglutaminase (e.g., with altered substrate specifity); and 2) amine donor agents comprising amine donor units, linkers, and agent moieties, wherein the DAR is at least about 5. The invention also provides methods of making and methods of using such higher drug loaded antibody-drug conjugates.

Antibody-drug conjugates with high drug loading

The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and other heterodimeric proteins comprising immunoglobulin-like hinge sequences. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided.

Heterodimeric proteins and methods for producing and purifying them

The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.

Anti-PD-1 antibodies and methods of use thereof

Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.

Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)

The present invention relates to bispecific antibodies that specific bind to BCMA (B-Cell Maturation Antigen) and CD3 (Cluster of Differentiation 3). Method of making the bispecific antibodies and method of using the bispecific antibodies for the treatment of multiple myeloma are also provided.

Growing community of inventors

San Francisco, CA, United States of America

Arvind Rajpal